Business Wire

Lawyer for Aviator LLC Details Origin of Aviator Logo Following Court Victory

4.9.2024 11:00:00 EEST | Business Wire | Press release

Share

After winning an important $330 million infringement ruling by the Georgian Court of First Instance against Adjarabet and Spribe OÜ, and in response to statements published in the media by the defendants, Nikoloz Gogilidze, Managing Partner of the law firm Mikadze Gegetchkori Taktakishvili LLC which represents Aviator LLC, says that the Aviator brand (the name and the logo) was created in 2016-2017 by Georgian businessman Teimuraz Ugulava.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904224604/en/

Left image: Original logo owned by Aviator LLC, used illegally in Georgia by Adjarabet and Spribe OÜ until January 2024. Right image: Modified logo used internationally by Spribe OÜ, invalidated by Aviator LLC in Georgia. (Graphic: Business Wire)

Mr. Gogilidze shares further history of the ownership of the brand, as detailed in submissions before the court:

In 2018, the “Aviator” trademark was duly registered with the Georgian State Trademark Agency (Sakpatenti; www.sakpatenti.gov.ge/en) by City Loft LLC, company solely owned by Teimuraz Ugulava. In 2018, Mr. Ugulava owned two gambling companies, the land casino Aviator and the online platform Adjarabet. The design of Aviator logo was initially used for the land casino Aviator. At the same time, Adjarabet, which was also owned by Ugulava, launched the crash game Aviator in collaboration with Spribe OÜ. As the creation of the game was financed by Adjarabet (while still under Termuraz Ugulava’s ownership), City Loft provided its bare consent for Adjarabet to use the same Aviator logo and airplane image.

Gogilidze says that Aviator crash game was launched on the Adjarabet online casino in January 2019, when the company was still 100% owned by Teimuraz Ugulava. Soon after launching the game, Adjarabet was sold to Flutter Entertainment Plc. None of the agreements executed with Flutter provided any rights to the Aviator trademarks. Moreover, the Agreement provided the list of trademarks transferred to the purchaser as a result of the share sale, which included the brand “Adjarabet”, also registered in the State Trademark Agency back at the time, but not the trademark “Aviator.”

Spribe OÜ and Adjarabet continued using the logo for the game on the Adjarabet platform in both the Georgian and Armenian markets until January 2024.

Gogilidze says that when Spribe OÜ decided to take the game outside Georgia, it deliberately made a slight modification to the logo and continued to use modified logo outside. At the same time, Spribe OÜ applied for registration of the modified logo in Georgia in 2022 and in the European Union in 2023.

As detailed in the court submissions, in 2022 all intellectual property related to the Aviator trademark and the airplane image was transferred from City Loft to Aviator LLC, a gaming company active in the land casino sector in Georgia. In order to protect its IP rights, Aviator LLC brought the invalidation action before the Georgian courts against, amongst others, Spribe OÜ.

For further information and media queries, please contact Aviator LLC’s representatives at info.aviator@mikadze.ge.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904224604/en/

Contacts

Nikoloz Gogilidze, info.aviator@mikadze.ge

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye